Veteran private-equity investor focused on growth-stage technology and healthcare companies, specializing in buyouts, operational value creation and go-to-market scaling. Brandon Smith brings over a decade of cross-border investing and operating experience, having led platform investments, add-on acquisitions and board oversight across SaaS, digital health and enterprise software. Deeply involved in portfolio transformation, capital allocation and senior management recruitment, he is known for thesis-driven sourcing and exit execution. Investment remit typically targets $50m–$300m enterprise value companies and institutional LP relationships, with an emphasis on revenue growth, margin expansion and strategic M&A.
Veteran private-equity investor focused on growth-stage technology and healthcare companies, specializing in buyouts, operational value creation and go-to-market scaling. Brandon Smith brings over a decade of cross-border investing and operating experience, having led platform investments, add-on acquisitions and board oversight across SaaS, digital health and enterprise software. Deeply involved in portfolio transformation, capital allocation and senior management recruitment, he is known for thesis-driven sourcing and exit execution. Investment remit typically targets $50m–$300m enterprise value companies and institutional LP relationships, with an emphasis on revenue growth, margin expansion and strategic M&A.
Focuses on growth-stage technology and healthcare buyouts, prioritizing scalable SaaS, digital health, and enterprise software businesses where operational interventions and go-to-market scaling can unlock value. Applies a thesis-driven sourcing model, targets $50m–$300m enterprise value platforms, and pursues add-on M&A to accelerate consolidation. Capital allocation balances minority growth rounds with control buyouts to drive revenue growth and margin expansion over a 3–7 year exit horizon. Risk disciplined through active board oversight, management recruitment, and performance-linked operational KPIs to de-risk exits for institutional LPs.
Focuses on growth-stage technology and healthcare buyouts, prioritizing scalable SaaS, digital health, and enterprise software businesses where operational interventions and go-to-market scaling can unlock value. Applies a thesis-driven sourcing model, targets $50m–$300m enterprise value platforms, and pursues add-on M&A to accelerate consolidation. Capital allocation balances minority growth rounds with control buyouts to drive revenue growth and margin expansion over a 3–7 year exit horizon. Risk disciplined through active board oversight, management recruitment, and performance-linked operational KPIs to de-risk exits for institutional LPs.
| Trades 317 | Longs Won 256/317 80% | Profit Factor 65.07 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $540,542.42 |
| Average Win $172,463.26 | Best Trade (Jul 10) $8.53M | Sharpe Ratio -12.1 |
| Average Loss -$11,123.42 | Worst Trade (Jul 14) -$134,200 | Z-Score 19.58 (100%) |
| Commissions $0 | Avg. Trade Length 10m 1w 6d | Expectancy $137,135.85 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 17,544 | 15,789 | 14,035 | 12,281 | 10,526 | 8,772 | 7,018 | 5,263 | 3,509 | 1,754 |